Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from NIH

Adam ruins government & criticizes Obama

Netflix's "The G Word" host tells Salon government is "astonishing" when it works and how to stop doomscrolling

Salon

Commentary: One monkey’s story

I want to tell you a story. It’s about a prisoner—a prisoner who has endured horrors the likes of which we can scarcely imagine.

Tribune News Service

Biden Says US Ready To Share COVID-19 Vaccine Related Technology

President Joe Biden said that the U.S. will share technologies used to make COVID-19 vaccines through the World Health Organization and is working on expanding rapid testing and antiviral treatments for hard-to-reach populations. "We are making available health technologies that are owned by the United States government, including stabilized spike protein that…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why a US task force is recommending anxiety screening in kids 8 and older

The U.S. Preventive Services Task Force issued a draft statement in April 2022 recommending screening for anxiety in children and adolescents between the ages of 8 and 18. This recommendation – which is still open for public comment – is timely, given the impact of the COVID-19 pandemic on children’s…

The Conversation

Senators Cory Booker And Brian Schatz Call On Federal Agencies To Research Psychedelics

Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the FDA whom they called on to study the therapeutic potent

Benzinga

How one professor's work to save teachers' voices is part of new research focus

PHILADELPHIA — Managing a classroom takes a lot, including a strong voice that can lift over the chatter of 30-some students.

The Philadelphia Inquirer

Two long COVID Patients Recover After Pfizer's Therapy; Side Effects, Safety Needs To Be Assessed: Reuters

Reuters reported that two patients found relief from long COVID after taking Pfizer Inc's (NYSE:PFE) antiviral Paxlovid, including a researcher who tested it on herself. Long COVID is estimated to affect up to 30% of people infected with the coronavirus. It can last for months. More than 200 symptoms have been associated with the…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Gilbert Gottfried had myotonic dystrophy before his death. What is the rare disease?

Comedian Gilbert Gottfried died on Tuesday after a long illness, his family announced.

Tribune News Service

Do IBCs benefit biomedical research?

Experts say IBCs are a crucial tool for ensuring the safety of biomedical research. Critics say they are too opaque

Salon

How long Covid is accelerating revolution in medical research

Scientists are empowering patients to assist with medical research about long Covid and other conditions

The Independent UK

What is aphasia, disorder Bruce Willis was diagnosed with, and how is it treated?

Disorder has been ‘impacting’ Willis’ ‘cognitive abilities,’ his family says

The Independent UK

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Axios

What is aphasia, disorder Bruce Willis was diagnosed with, and how is it treated?

Disorder has been ‘impacting’ Willis’ ‘cognitive abilities,’ his family says

The Independent UK

Want a personalized diet to prevent disease? Nutrition scientists are working on it

Instead of taking a typical hypothesis-driven approach, precision nutrition researchers now collect data to study an individual’s DNA, gut microbiome, metabolism and response to what they eat, and are able to determine how it affects a person’s psychological and biological profile.

Chicago Sun-Times

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

New data-sharing requirements from the National Institutes of Health are a big step toward more open science – and potentially higher-quality research

Starting on Jan. 25, 2023, many of the 2,500 institutions and 300,000 researchers that the U.S. National Institutes of Health supports will need to provide a formal, detailed plan for publicly sharing the data generated by their research. For many in the scientific community, this new NIH Data Management and…

Reason

NIH Awarded More Than 56,000 Grants in 2020. Just 2 Percent Were for Studying COVID.

More evidence that the public health bureaucracy dropped the ball when a once-in-a-generation pandemic hit.

The Independent UK

Big US gene database has volunteers from all walks of life

Scientists are getting their first peek at the genes of nearly 100,000 Americans in what's considered a uniquely diverse genomic database

Benzinga

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Moderna co-founder Robert Langer: ‘I wanted to use my chemical engineering to help people’

The celebrated US scientist and inventor on not being in it for the money, why diversity improves problem-solving, and his dedication to exercising

Benzinga

NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185

SAB Biotherapeutics Inc (NASDAQ:SABS) said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19 trial. SAB-185 was being assessed as part of Phase 3 ACTIV-2 master protocol evaluating treatments for COVID-19 in patients with…

Salon

The loophole to lower drug prices

A provision known as "march-in rights" lets the government intervene if drugs are being sold at unreasonable prices

Los Angeles Times

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

Benzinga

ACHV: The Final Phase III Begins

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

The Guardian - US

The great gaslighting: how Covid longhaulers are still fighting for recognition

People with long Covid face an uphill battle convincing skeptics their malady is real – but discrediting uncommon conditions is hardly a new phenomenon

Benzinga

On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial

SAB Biotherapeutics Inc (NASDAQ: SABS) has

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.